Structure-Based Design of Nonpeptidic HIV Protease Inhibitors:  The Sulfonamide-Substituted Cyclooctylpyranones

Skulnick, Harvey I.; Johnson, Paul D.; Aristoff, Paul A.; Morris, Jeanette K.; Lovasz, K. D.; Howe, W. Jeffrey; Watenpaugh, Keith David; Janakiraman, M.N.; Anderson, David J.; Reischer, Robert J.; Schwartz, Theresa; Banitt, Lee S.; Tomich, Paul K.; Lynn, Janet C.; Horng, Miao-Miao; Chong, K. T.; Hinshaw, Roger R.; Dolak, Lester A.; Seest, Eric P.; Schwende, Francis J.; Rush, Bob D.; Howard, G.M; Toth, L. N.; Wilkinson, Kay; Kakuk, Thomas J.; Johnson, Claire; Cole, Serena L.; Zaya, Renee M.; Zipp, G.L; Possert, P.L; Dalga, R J; Zhong, Wei-Zhu; Williams, Marta G.; Romines, Karen R.

doi:10.1021/jm960441m

Cited by 83 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5] began with nitration of 4Ј,5Ј-dimethylfluorescein, where the methyl substituents confined nitration to the 2Ј,7Ј positions. Reduction of the nitro groups yielded 4Ј,5Ј-dimethyl-2Ј,7Ј-diaminofluorescein, which was reacted with 2 equivalents of 2-pyridylsulfonyl chloride (23) to give the desired fluorescent chelator. Formation of the Zn-dye complex shifts fluorescence excitation/emission maxima from 515/545 nm to 534/560 nm (Fig.…”

Section: Resultsmentioning

confidence: 99%

A hexahistidine-Zn ²⁺ -dye label reveals STIM1 surface exposure

Hauser¹,

Tsien

2007

Proc. Natl. Acad. Sci. U.S.A.

148

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A hexahistidine-Zn ²⁺ -dye label reveals STIM1 surface exposure

Hauser¹,

Tsien

2007

Proc. Natl. Acad. Sci. U.S.A.

148

View full text Add to dashboard Cite

“…64 Many tipranavir-like derivatives were also reported possessing different substitution patterns at the arylsulfonamide, C-3a and C-6 positions of the heterocyclic ring, or incorporating a 6-hydroxy-1,3-dioxin-4-one moiety instead of the coumarone one, of types 76-78. [70][71][72] Many such derivatives exhibited low nanomolar affinity for the wild type and mutated HIV PRs. [70][71][72] Indinavir 79 is one of the most widely clinically used PIs.…”

Section: H I V P R O T E a S E I N H I B I T O R Smentioning

confidence: 99%

“…[70][71][72] Many such derivatives exhibited low nanomolar affinity for the wild type and mutated HIV PRs. [70][71][72] Indinavir 79 is one of the most widely clinically used PIs. It possesses an IC 50 value of 0.41 nM against HIV PR and a good water solubility of 70 mg/mL, being thus orally bioavailable.…”

Section: H I V P R O T E a S E I N H I B I T O R Smentioning

confidence: 99%

Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents

Supuran

Casini

Scozzafava

2003

Medicinal Research Reviews

398

153

View full text Add to dashboard Cite

The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic, and antithyroid activity among others. A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial protease inhibitory properties. Of particular interest are some metalloprotease inhibitors belonging to this class, which by inhibiting several matrix metalloproteases (MMPs) show interesting antitumor properties. Some of these compounds are currently being evaluated in clinical trials. The large number of sulfonamide MMP inhibitors ultimately reported also lead to the design of effective tumor necrosis factor-alpha converting enzyme (TACE) inhibitors, potentially useful in the treatment of inflammatory states of various types. Since both MMPs and TACE contribute synergistically to the pathophysiology of many diseases, such as arthritis, bacterial meningitis, tumor invasion; the dual inhibition of these enzymes emerged as an interesting target for the drug design of anticancer/antiinflammatory drugs, and many such sulfonamide derivatives were recently reported. Human neutrophyl elastase (HNE) inhibitors of the sulfonamide type may also be useful in the treatment of inflammatory conditions, such as emphysema, cystic fibrosis, chronic bronchitis, ischemia reperfusion injury, and acute respiratory distress syndrome. Inhibition of some cysteine proteases, such as several caspase and cathepsin isozymes, may lead to the development of pharmacological agents effective for the management of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, brain damage, and stroke. Another research line that progressed much in the last time regards different sulfonamides with remarkable antiviral activity. Some clinically used HIV protease inhibitors (such as amprenavir) possess sulfonamide moieties in their molecules, which are critical for the potency of these drugs, as shown by means of X-ray crystallography, whereas a very large number of other derivatives are constantly being synthesized and evaluated in order to obtain compounds with lower toxicity or augmented activity against viruses resistant to the such first generation drugs. Other viral proteases, such as those isolated from several types of herpes viruses may be inhibited by sulfonamide derivatives, leading thus to more effective classes of antiviral drugs.

show abstract

“…Therapeutic intervention for genital viral infections are under development and include nucleoside analogues and protease inhibitors (Skulnick et al, 1997). However, for most of the viral diseases a curative treatment concept is still missing.…”

Section: Viral Infectionsmentioning

confidence: 99%